Posted by undopaminergic on June 20, 2020, at 5:53:55
In reply to Re: Can someone explain this COVID/MAO-B study?, posted by linkadge on June 19, 2020, at 15:01:00
> Great article and question.
>
> I've always been interested in MAO-B. Generally speaking, MAO-B activity is thought to increase with age. It also appears to be increased in depression (especially depression with cognitive disturbance). MAO-B inhibitors are used for Parkinson's disease, but also appear to have pro-cognitive effects (i.e. selegiline is approved for canine cognitive dysfunction).
>What about rasagiline? It could be the (l-) amphetamine metabolites of selegiline.
PEA can most definitely have pro-cognitive effects, especially in ADHD, but I'm not sure this is true at physiological (natural) PEA levels, because my experience is with exogenous PEA and, on top of it, under MAO-B inhibition with selegiline.
> This study doesn't directly say whether MAO-B levels are elevated (or depressed) in patients with COVID associated delirium.
>If that were so, I think the abstract would have stated that much. From what I read, it is about the differential concentrations in blood vs. CSF.
-undopaminergic
poster:undopaminergic
thread:1110832
URL: http://www.dr-bob.org/babble/20200511/msgs/1110874.html